Biotech Archives - Page 708 of 795

1 minute read

Gamida Cell Presents Data Demonstrating The Impact Of Transplantation With Omidubicel For Patients With Hematologic Malignancies At 2022 Cord Blood Connect Meeting

September 12, 8:16 AM

- Patients treated with omidubicel reported higher health-related quality of life scores during first-year post-transplant as compared to transplantation with umbilical cord blood (UCB) - If approved, Omidubicel is

GMDA

3 minute read

NuCana Presents Data On NUC-3373 At The European Society Of Medical Oncology Annual Meeting 2022

By Benzinga Newsdesk

September 12, 8:10 AM

NUC-3373 Demonstrates Promising Anti-Tumor Activity and Safety in Combination with Oxaliplatin (NUFOX) and Irinotecan (NUFIRI) in Heavily Pre-Treated Colorectal Cancer Patients Randomized Study of NUFIRI vs.

NCNA

3 minute read

Onconova Therapeutics Announces Updated Data From Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib In Combination With Nivolumab In Advanced KRAS-Mutated Non-Small Cell Lung Cancer At The ESMO Congress 2022

By Bill Haddad

September 12, 8:04 AM

Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patients Responses achieved in patients with 3

ONTX

1 minute read

Phio Pharmaceuticals Announces Acceptance Of Six Abstracts At The 37th Annual Meeting Of The Society For Immunotherapy Of Cancer

By Bill Haddad

September 12, 7:34 AM

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today

PHIO

1 minute read

Alector Initiates Phase 1 Clinical Trial Of AL044 For The Treatment Of Alzheimer’s Disease

By Benzinga Newsdesk

September 12, 7:12 AM

AL044 is the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for AD AL044, a novel first-in-class therapeutic candidate, seeks to counteract multiple AD pathologies through

ALEC

3 minute read

Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During ‘Spotlight on the Clinic’ Virtual Event

By Bill Haddad

September 12, 7:06 AM

- Presentation and Discussion with Two Leading Neuromuscular Disease Experts - - Data from DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Anticipated in the Second Half of 2023 - - Refined Focus on

DYN

3 minute read

Allakos Announces Initiation Of Phase 2b Clinical Trial Of Subcutaneous Lirentelimab In Chronic Spontaneous Urticaria

By Benzinga Newsdesk

September 12, 7:04 AM

Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced it has initiated a Phase 2b clinical trial to

ALLK

1 minute read

Can-Fite Reports New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented By KOL Dr. Papp At The 31st European Academy Of Dermatology

By Benzinga Newsdesk

September 12, 7:02 AM

Dr. Papp: "The safety results on Piclidenoson and its progressive effectiveness over the study period position it as unique among the current treatment options especially given the chronic nature of psoriasis

CANF

1 minute read

Keros Therapeutics Presents Additional Clinical Data From Its KER-012 Program And Preclinical Data From Its KER-050 Program At The American Society Of Bone And Mineral Research 2022 Annual Meeting

By Benzinga Newsdesk

September 12, 6:01 AM

Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from

KROS

1 minute read

Bristol Myers’ Deucravacitinib Scores FDA Approval For Plaque Psoriasis

By Vandana Singh

September 12, 6:00 AM

The FDA approved Bristol Myers Squibb Co’s (NYSE:BMY) Sotyktu (deucravacitinib), an allosteric tyrosine kinase 2 (TYK2) inhibitor, for moderate-to-severe plaque psoriasis…

AMGN